Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Primary Mediastinal Large B-cell Lymphoma (PMBCL): early-phase trial registry
4 of 8 indexed Primary Mediastinal Large B-cell Lymphoma (PMBCL) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,176 of 28,707 conditions by registered trial count.
8 US clinical trials · 4 currently recruiting · #2,176 of 28,707 conditions by registered trial count
Primary Mediastinal Large B-cell Lymphoma (PMBCL): 8 US clinical trials tracked, 4 recruiting.
Primary Mediastinal Large B-cell Lymphoma (PMBCL) is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is Tessa Therapeutics, running 1 of these trials.
Enrollment posture brief
Registry condition primary-mediastinal-large-b-cell-lymphoma-pmbcl
OPEN 4 | RECR 50% | LATE 0 | EARLY 8 | RANK #2176 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Primary Mediastinal Large B-cell Lymphoma (PMBCL) lists 4 open slots (50% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Primary Mediastinal Large B-cell Lymphoma (PMBCL) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Primary Mediastinal Large B-cell Lymphoma (PMBCL) is recruiting above its size-band peers.
4 of 8 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Primary Mediastinal Large B-cell Lymphoma (PMBCL) trials is spread across many organizations.
Tessa Therapeutics accounts for 1 of 8 trials (12.5%). 8 distinct sponsors appear on at least one study for this condition label.
-
Most Primary Mediastinal Large B-cell Lymphoma (PMBCL) trials plan to enrol fewer than 100 people.
Median target enrolment is 66 among the 8 trials that report a genuine target (sentinel values excluded). 5 of those (62.5%) plan for fewer than 100 participants.
-
Primary Mediastinal Large B-cell Lymphoma (PMBCL) research is mostly interventional.
8 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
8 total, page 1 of 1
P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
Poseida Therapeutics
NCT06014762
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
Medical College of Wisconsin
NCT04186520
Pembro Plus CAR T-cell Therapy in R/R in PMBCL
Jennifer Crombie, MD
NCT05934448
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Marcela V. Maus, M.D.,Ph.D.
NCT06026319
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
Genmab
NCT03625037
Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy
H. Lee Moffitt Cancer Center and Research Institute
NCT04745559
Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma
Tessa Therapeutics
NCT04526834
A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)
Merck Sharp & Dohme
NCT04875195
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Primary Mediastinal Large B-cell Lymphoma (PMBCL) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Primary Mediastinal Large B-cell Lymphoma (PMBCL) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Primary Mediastinal Large B-cell Lymphoma (PMBCL) page
8 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Primary Mediastinal Large B-cell Lymphoma (PMBCL) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Tessa Therapeutics sponsors the most Primary Mediastinal Large B-cell Lymphoma (PMBCL) trials on record, review their full trial history before evaluating a specific study. See Tessa Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Primary Mediastinal Large B-cell Lymphoma (PMBCL) condition card totals 8 registered trials; most-linked intervention CD19 targeted CAR T Cell Therapy; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.